Alizapride

Author:Prof. Dr. med. Peter Altmeyer

Last updated on: 29.10.2020

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).

Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Antiemetic, dopamine antagonist.

IndicationThis section has been translated automatically.

Prophylactically for cytostatic-induced vomiting, radiation damage or post-operatively.

Limited indicationThis section has been translated automatically.

Pregnancy, renal insufficiency.

Dosage and method of useThis section has been translated automatically.

For cytostatic drug therapy 150 mg p.o. before and 150 mg after cytostasis, 3 times 50 mg p.o. the following day. Alternatively 100 mg i.v. before and 100 mg i.v. or i.m. after cytostatic drug application.

Undesirable effectsThis section has been translated automatically.

CNS disorders, dizziness, RR decline, diarrhea, dry mouth, amenorrhea.

InteractionsThis section has been translated automatically.

Table 1.

ContraindicationThis section has been translated automatically.

Children < 14 years, pheochromocytoma, late dyskinesia, prolactinoma.

PreparationsThis section has been translated automatically.

Vergentan

TablesThis section has been translated automatically.

Key interactions of alizapride

Alimemazine	extrapyramidal symptoms ↑
Anticholinergics	mutual effect ↓
Alcohol	central attenuation
Chlorphenethazine	extrapyramidal symptoms ↑
Lisurid	Lisuride effect ↓
Mequitazine	extrapyramidal symptoms ↑
Neuroleptics	extrapyramidal symptoms ↑, avoid combination
Scopolamine	Scopolamine effect ↓
CNS damping agent	central damping ↑

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer